Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Allogene Therapeutics news
01.03.2023
Allogene Therapeutics' GAAP loss for 2022 was $332.63 million, up 29.4% from $257 million the previous year. Revenues were down multiple times, at $0.243 million, compared to $38.489 million a year earlier.
Source: 
ir.allogene.com
ir.allogene.com
03.11.2022
Allogene Therapeutics reported a GAAP loss of $237.785 million for 9 months of 2022, up 30.6% from $182.137 million in the prior year. Revenue decreased 99.5% to $0.196 million from $38.438 million a year earlier.
Source: ir.allogene.com
ir.allogene.com
10.08.2022
Allogene Therapeutics' GAAP loss for 6 months of 2022 was $154.64 million, up 48.8% from $103.95 million in the previous year. Revenues declined multiple times, totaling $0.147 million versus $38.389 million a year earlier.
Source: ir.allogene.com
ir.allogene.com
05.05.2022
Allogene Therapeutics' GAAP net income for 3 months of 2022 was $79.85 million, up 2.4 times from $33.015 million in the previous year. Revenues decreased many-fold, amounting to $0.061 million compared to $38.345 million a year earlier.
Source: ir.allogene.com
ir.allogene.com
General information
| Company name | Allogene Therapeutics |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700 |
| Mailing address | 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 |
| Website | www.allogene.com |
| Information disclosure | www.sec.gov |
English (US) 